查看购物车
  • Traditional Chinese
  • English
  • Japanese
生物製药研发市场－全球及区域分析：依方法、生产类型、类型及地区划分－分析与预测（2025-2035）
市场调查报告书
商品编码
1871069

生物製药研发市场－全球及区域分析：依方法、生产类型、类型及地区划分－分析与预测（2025-2035）

Biologics Drug Discovery Market - A Global and Regional Analysis: Focus on Method, Manufacturing Type, Type, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 189 Pages | 商品交期: 1-5个工作天内

价格

这份报告可以在一个工作天内送达。

生物製药研发市场简介

2024年全球生物製药研发市场规模为213.4亿美元，预计到2035年将显着成长至630.7亿美元，2025年至2035年的复合年增长率将达到10.38%。

关键市场统计数据
预测期 2025-2035
截至2025年的估值 234.9亿美元
2035 年预测 630.7亿美元
复合年增长率 10.38%

生物製药研发市场正经历稳定成长，这主要得益于慢性病和罕见疾病病例的增加、对精准标标靶治疗的需求不断增长以及治疗策略向更有效的作用机制导向型治疗方法的转变。单株抗体、重组蛋白和新一代疗法等生物製剂因其优于传统小分子化合物的选择性和治疗效果而备受关注。政府支持的研发资金、公私合营以及有利的法规结构等扶持措施，进一步加速了创新，并扩大了生物製剂在肿瘤学、免疫学和神经病学等治疗领域的应用。

快速的技术进步也正在改变生物製药研发的格局，人工智慧辅助标靶辨识、高通量筛检、单细胞分析和抗体工程等技术提高了早期研发的效率和成功率。儘管取得了这些进展，但高昂的研发成本、复杂的生产流程以及研究基础设施和人才的区域差异等挑战仍然是规模化生产的重要障碍。然而，持续的全球投资、不断扩展的外包模式以及对个人化医疗日益增长的需求，预计将在未来十年内将生物製药研发打造成为下一代治疗创新的基石。

市场介绍

在药物发现平台和策略联盟的持续创新驱动下，生物製药研发市场正经历重大变革。各公司积极采用高通量筛检、人工智慧驱动的药物发现平台和先进的抗体库等尖端技术，以提高治疗药物研发的速度和准确性。 Alloy Therapeutics 的 mAbForge 高通量筛检服务、百奥赛图製药（北京）有限公司的 RenBiologics 抗体平台以及 Evotec SE 的 J.CHO 超表达系统等知名产品的推出，体现了业界对提高生物製剂研发效率和扩充性的重视。随着生物製药在满足肿瘤学、免疫学和罕见疾病领域未被满足的临床需求方面的重要性日益凸显，这些创新有望重塑药物研发格局，并将生物製药定位为下一代治疗药物研发的基石。

对产业的影响

在精准标靶治疗需求不断增长以及个人化医疗日益受到重视的推动下，全球生物製药研发市场正经历着深刻的变革时期。 Alloy Therapeutics、Charles River Laboratories International、Regeneron Pharmaceuticals 和 WuXi Biologics (Cayman) Inc. 等主要企业在推动生物製药研发技术方面发挥着核心作用，支持着超越传统疗法的新型治疗方法的开发。这些创新在肿瘤学、免疫学和罕见疾病等领域至关重要，能够实现更有效率、更具针对性的药物研发，并改善治疗效果。透过提高候选药物辨识的速度和准确性、降低研发成本以及促进全球合作，生物製药研发有助于建立更有效率、更精简的治疗方案开发流程。生物製剂生物製药研发与全球精准医疗的转型相契合，进一步增强了其市场影响力，使其成为下一代治疗进步的基石。

市场区隔:

类别 1：依方法

  • 目标识别与检验
  • 命中创建/检验
  • 先导化合物鑑定
  • 先导药物最适化

先导化合物的发现/检验推动了生物製药发现市场（按方法划分）

依方法论划分，全球生物製药研发市场将以先导化合物发现/检验主导，预计到2024年将占28.8%的市场份额。该领域在生物製药开发的早期阶段至关重要，因为识别潜在的候选药物（例如抗体疗法）对于治疗计画的成功至关重要。目前应用最广泛的先导化合物发现/检验方法包括噬菌体展示筛检和融合瘤筛检，这两种方法对于产生和检验高亲和性抗体都至关重要。噬菌体展示技术能够快速筛检大型抗体库以识别特定的候选药物，而融合瘤筛检仍是单株抗体生产的基础。随着精准医疗需求的不断增长，这些方法对于发现新的生物製药至关重要，尤其是在癌症和自体免疫疾病等复杂疾病的治疗方面。先进技术的日益普及反映了它们在加速生物製药药物研发进程和推动市场持续成长方面的重要作用。

细分2：依生产类型

  • 内部生产
  • 外包委託製造

内部生产是生物製药研发市场的主要驱动力（按生产类型划分）。

按生产类型划分，内部生产在生物製药研发市场中占据主导地位，预计到2024年将占65.3%的市场份额。由于在品管、智慧财产权保护和成本管理方面具有优势，内部生产仍然是首选方法。然而，随着越来越多的公司寻求降低营运成本、提高扩充性并获取专业知识，预计从2025年到2035年，外包生产市场将以11.2%的复合年增长率成长。外包使公司能够利用合约生产组织（CMO）提供的契约製造技术，例如高通量筛检和大规模生物製药生产，而无需大量资本投资。随着中小型生物技术和製药公司越来越依赖外部合作伙伴进行生物製药（包括单株抗体、重组蛋白以及细胞和基因疗法）的发现、开发和生产，这种转变尤其明显。生物製药需求的不断增长，以及生产流程对灵活性和效率的更高要求，预计将推动外包产业的持续成长，而外包产业有望成为生物製药研发市场扩张的重要因素。

细分3：按类型

  • 单株抗体
  • 重组蛋白
  • 其他生物製药

其他推动生物製药生物製药（按类型划分）

按类型划分，全球生物製药研发市场将由其他生物製药细分市场主导，预计到2024年将占据43.8%的市场份额。该细分市场的主导地位归功于对创新治疗方法和治疗策略的日益重视，例如个人化医疗、免疫疗法和先进疫苗的研发。疫苗需求的激增，尤其是在全球健康危机之后，加速了疫苗生产和研发的步伐。同样，旨在解决以往难以治癒的遗传疾病的细胞和基因疗法的快速发展，也引起了公共和私营部门的广泛关注。此外，对包括干细胞和基因编辑技术在内的细胞疗法研发投入的不断增加，预计将推动该细分市场的持续成长。此类别治疗方法的多样性，加上慢性病和遗传病患疾病率的上升，使得其他生物製药细分市场成为整个生物製药市场的关键驱动力。

细分 4：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 其他的
  • 其他地区

预计亚太地区将在生物製药研发市场中实现最高的区域成长率。

预计2025年至2035年预测期内，亚太地区生物製药研发市场将以11.9%的显着速度成长。这一快速成长主要受以下几个关键因素驱动：生物技术研发投入的增加、医疗基础设施的不断完善以及对个人化医疗日益增长的关注。亚太地区医疗卫生体系多元化且发展迅速，生物製剂领域正取得显着进展。各国政府和私人机构，特别是中国、日本、印度和韩国等国家，正大力投资生物製药研发。该地区人口众多且老化严重，加上癌症、糖尿病和自体免疫疾病等慢性病负担日益加重，迫切需要创新型生物疗法。此外，CRISPR和基因编辑等尖端技术的日益普及，以及细胞和基因疗法的进步，预计将进一步巩固该地区在生物製药研发领域的领先地位。亚太市场也受益于人们对生物相似药日益增长的关注，因为生物相似药是昂贵的生物疗法的经济有效的替代品，这使得全部区域更广泛的患者群体更容易获得这些治疗方法。

生物製药研发市场的最新趋势

  • 2025 年 6 月，艾伯维公司收购了 Capstan Therapeutics 公司，以利用该公司的标靶脂质奈米颗粒 (tLNP) 平台，推进自体免疫疾病的 CAR-T 疗法的开发。
  • 2025 年 1 月，Evotec SE 与延世大学和韩国生物技术公司 Zymedi 合作，获得了韩国先进技术研究院 (KIAT) 450 万美元的津贴，用于开发治疗气喘和特发性肺纤维化 (IPF) 等肺部疾病的First-in-Class生物疗法。
  • 2024 年 1 月，百奥赛图医药（北京）有限公司推出子品牌“RenBiologics”，致力于授权其全人源抗体库和 RenMice 药物发现平台，从而实现全球伙伴关係和基于抗体的疗法的共同开发。

需求——驱动因素、挑战与机会

市场驱动因素

慢性病和罕见疾病病例增加推动生物製剂需求—对慢性病和罕见疾病创新治疗方法的需求日益增长，推动了创新生物製剂的需求及其研发。癌症、自体免疫疾病和心血管疾病等慢性病持续为全球医疗保健系统带来挑战。能够针对特定分子路径的生物製剂为这些复杂疾病提供了有效的解决方案。此外，罕见疾病的盛行率不断上升，而这些疾病往往缺乏有效的治疗方法，这进一步凸显了生物製药在满足未被满足的医疗需求方面的重要性。单株抗体、重组蛋白、基因疗法和酵素替代疗法等治疗方法在治疗这些疾病方面发挥主导作用。随着全球医疗保健格局的演变和对先进标靶治疗方法需求的增加，新型生物製药的发现有望在塑造医疗保健的未来方面发挥关键作用。

市场挑战

高昂的研发和生产成本－生物製药的发现、开发和生产高成本，对市场成长构成重大挑战。生物製药，尤其是处于研发或后期开发阶段的生物製剂，需要在研究、生产和品管方面投入大量资金。这些流程复杂且资源密集，通常涉及最尖端科技、专用设施和严格的监管要求。因此，生物製药往往比传统小分子药物更昂贵，限制了其可近性，尤其是在资源有限或对成本敏感的医疗环境中。此外，生物疗法的高昂价格，加上持续研发的需求，给医疗系统和患者带来了经济压力。这些经济障碍限制了服务不足地区和经济困难人口获得生物製药的机会。克服这些挑战对于推进生物製药研发、扩大生物疗法的覆盖范围以及确保其在各种医疗环境中得到更广泛的应用至关重要。

市场机会

人工智慧在生物製药研发中的应用－将人工智慧（AI）融入生物製药药物研发流程，可望大幅提升生物疗法的研发速度、效率和成本效益，从而带来巨大的发展机会。包括机器学习和深度学习在内的人工智慧技术，能够更精准地预测分子交互作用，优化药物设计，并简化新型生物製药。北美和欧洲等专注于创新和先进医疗技术的地区，在将人工智慧融入生物製药研发方面取得了显着进展。此外，生物製药公司与人工智慧技术供应商之间的合作也不断加强，进一步提升了生物製药药物研发平台的能力。

全球生物製药研发市场已根据技术、生产类型、类型、地区等各种类别进行了详细细分。这有助于读者清楚了解哪个细分市场占据最大份额，以及未来几年该细分市场预计将在哪些方面成长。

伙伴关係、联盟和业务扩张是主要发展趋势，约占 2022 年 1 月至 2025 年 9 月全球生物製药发现市场所有趋势的 74%。

竞争策略：全球生物製药研发市场由众多拥有丰富产品系列的成熟企业所组成。本研究分析介绍的全球生物製药研发市场主要企业包括提供生物製药研发平台、产品和服务的知名公司。

主要市场参与企业及竞争摘要

目标公司的选择依据是公司概况、产品系列和市场渗透率的分析所收集的资讯。

该市场的主要企业包括：

  • Alloy Therapeutics, Inc.
  • Charles River Laboratories International, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • WuXi Biologics (Cayman) Inc.
  • AbbVie Inc.
  • Amgen, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Novo Nordisk A/S
  • Novartis AG
  • Evotec SE
  • Eli Lilly and Company
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Johnson & Johnson
  • Pfizer, Inc.
  • F. Hoffmann-La Roche AG

目录

执行摘要

第一章 全球生物製药研发市场：产业展望

  • 市场概览
  • 主要市场趋势
    • 双特异性和多特异性抗体研发进展
    • 加强伙伴关係与合作
    • 对外包服务的需求不断增长
  • 监管状态
    • 美国
    • 欧洲
    • 亚太地区
    • 其他地区
  • 供应链分析
    • 供应炼及其风险
  • 专利分析
  • 市场动态
    • 市场驱动因素
    • 市场挑战
    • 市场机会

2. 2023-2035年全球生物製药研发市场（依方法论划分）

  • 目标识别/检验
    • 功能基因体学/蛋白质体学
    • 基于细胞的检测
    • CRISPR/基因敲除研究/Cas9
    • 动物/疾病模型
    • 计算科学/In Silico/生物资讯学
  • 命中率产生/检验
    • mAb定序
    • 融合瘤筛检
    • 客製化合成资料库筛选
    • 噬菌体展示筛检
    • 高通量筛检
    • 其他的
  • 铅识别
    • 噬菌体展示
    • ELISA/ADCC 和 CDC 检测
    • 基于阵列的筛检
    • 融合瘤筛检及人源化
    • 生物分析
    • 其他检测
  • 先导药物最适化
    • 人性化
    • 亲和性分析
    • 蛋白质工程
    • 体外/体内功效试验
    • 其他的

3. 2023-2035年全球生物製药研发市场（依生产类型划分）

  • 内部生产
  • 外包製造

4. 2023-2035年全球生物製药研发市场（依类型划分）

  • 单株抗体
  • 重组蛋白
  • 其他的

5. 2023-2035年全球生物製药研发市场（按地区划分）

  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区

第六章 竞争基准化分析与公司概况

  • 各公司的主要策略和发展
  • 公司简介
    • Alloy Therapeutics, Inc.
    • AbbVie Inc.
    • Amgen, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Charles River Laboratories International, Inc.
    • Eli Lilly and Company
    • Evotec SE
    • F. Hoffmann-La Roche AG
    • GenScript Biotech Corporation
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Novo Nordisk A/S
    • Novartis AG
    • Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • WuXi Biologics (Cayman) Inc.

第七章调查方法

Product Code: BHP0493SB

This report can be delivered within 1 working day.

Introduction of the Biologics Drug Discovery Market

The global biologics drug discovery market, initially valued at $21.34 billion in 2024, is projected to witness substantial growth, surging to $63.07 billion by 2035, marking a remarkable compound annual growth rate (CAGR) of 10.38% over the period from 2025 to 2035.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$23.49 Billion
2035 Forecast$63.07 Billion
CAGR10.38%

The biologics drug discovery market has been witnessing steady growth, driven by the rising prevalence of chronic and rare diseases, increasing demand for precision-targeted therapies, and the shift toward more effective mechanism-based treatments. Biologics such as monoclonal antibodies, recombinant proteins, and next-generation therapies are gaining traction due to their ability to deliver higher selectivity and therapeutic efficacy compared to traditional small molecules. Supportive initiatives, including government-backed R&D funding, public-private collaborations, and favorable regulatory frameworks, are further accelerating innovation and expanding adoption across therapeutic areas such as oncology, immunology, and neurology.

Rapid technological advances are also reshaping the biologics drug discovery landscape, with AI-driven target identification, high-throughput screening, single-cell analysis, and antibody engineering enhancing efficiency and success rates in early-stage development. Despite these tailwinds, challenges such as high development costs, complex manufacturing processes, and regional disparities in research infrastructure and talent remain significant barriers to scale. Nevertheless, continued global investment, expanding outsourcing models, and growing demand for personalized medicine are expected to establish biologics drug discovery as a cornerstone of next-generation therapeutic innovation over the coming decade.

Market Introduction

The biologics drug discovery market has been undergoing a significant transformation, driven by continuous innovation in discovery platforms and strategic partnerships. Companies are increasingly adopting cutting-edge technologies such as high-throughput screening, AI-driven discovery platforms, and advanced antibody libraries to enhance the speed and precision of therapeutic development. Notable product launches, including Alloy Therapeutics, Inc.'s mAbForge high-throughput screening service, Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s RenBiologics antibody platform, and Evotec SE's J.CHO High Expression System for continuous antibody manufacturing, reflect the industry's focus on improving efficiency and scalability in biologics development. As biologics continue to gain prominence in addressing unmet clinical needs in oncology, immunology, and rare diseases, these innovations are poised to redefine the landscape of drug discovery, positioning biologics as a cornerstone of next-generation therapeutic development.

Industrial Impact

The global biologics drug discovery market has been experiencing a significant shift, driven by the increasing demand for precision-targeted therapies and the growing focus on personalized medicine. Key players such as Alloy Therapeutics, Inc., Charles River Laboratories International, Inc., Regeneron Pharmaceuticals, Inc., and WuXi Biologics (Cayman) Inc. have been playing a central role in advancing biologics discovery technologies, supporting the development of novel therapies beyond traditional approaches. These innovations are crucial in areas such as oncology, immunology, and rare diseases, enabling more efficient and targeted drug development with improved therapeutic outcomes. By enhancing the speed and precision of candidate identification, reducing development costs, and facilitating global partnerships, biologics drug discovery is contributing to a more effective and streamlined therapeutic development process. The market's impact is further amplified by its alignment with the global shift toward precision medicine, positioning biologics as a cornerstone of next-generation therapeutic advancements.

Market Segmentation:

Segmentation 1: By Method

  • Target Identification/Validation
  • Hit Generation/Validation
  • Lead Identification
  • Lead Optimization

Hit Generation/Validation to Dominate the Biologics Drug Discovery Market (by Method)

Based on the method, the global biologics drug discovery market was led by hit generation/validation, which held a 28.8% share in 2024. This segment is essential in the early stages of biologics development, where identifying potential drug candidates, such as antibody therapeutics, is critical for the success of therapeutic programs. Among the most widely adopted methods in hit generation/validation are phage display screening and hybridoma screening, both of which are pivotal in generating and validating high-affinity antibodies. Phage display allows for the rapid screening of large antibody libraries to identify specific candidates, while hybridoma screening continues to be a cornerstone for monoclonal antibody production. As the demand for precision medicine grows, these methods are crucial in discovering new biologics, particularly for complex diseases such as cancer and autoimmune disorders. The growing adoption of advanced technologies reflects their vital role in accelerating the biologics drug discovery process and positioning the market for sustained growth.

Segmentation 2: By Manufacturing Type

  • In-House Manufacturing
  • Outsourced Manufacturing

In-house Manufacturing to Dominate the Biologics Drug Discovery Market (by Manufacturing Type)

Based on manufacturing type, the biologics drug discovery market was led by the in-house manufacturing segment, which held a 65.3% share in 2024. In-house production remains the preferred approach due to its control over quality, intellectual property, and cost management. However, the outsourced manufacturing segment is growing at a higher annualized growth rate (CAGR) of 11.2% from 2025 to 2035, as more companies seek to reduce operational costs, increase scalability, and access specialized expertise. Outsourcing enables companies to leverage contract manufacturing organizations (CMOs) for advanced technologies, such as high-throughput screening and large-scale biologics production, without the need for heavy capital investment. This shift is particularly evident as smaller biotech firms and pharmaceutical companies increasingly rely on external partners for the discovery, development, and manufacturing of biologics, including monoclonal antibodies, recombinant proteins, and cell and gene therapies. The rising demand for biologics, coupled with the increased need for flexibility and efficiency in the manufacturing process, is expected to drive continued growth in the outsourcing sector, making it an essential component of the biologics drug discovery market's expansion.

Segmentation 3: By Type

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Other Biologics

Other Biologics to Dominate the Biologics Drug Discovery Market (by Type)

Based on type, the global biologics drug discovery market was led by the other biologics segment, which held a 43.8% share in 2024. This segment's dominance can be attributed to the growing emphasis on innovative treatments and therapeutic strategies, such as personalized medicine, immunotherapies, and advanced vaccine development. The surge in demand for vaccines, particularly in the wake of global health crises, has accelerated the focus on vaccine production and research. Similarly, the rapid advancement of cell and gene therapies, which aim to address previously untreatable genetic disorders, has garnered substantial attention from both public and private sectors. Furthermore, the increased investment in the research and development of cell-based therapies, including stem cells and gene-editing technologies, is expected to drive the continued growth of this segment. The diversity of treatment approaches within this category, coupled with the rising prevalence of chronic diseases and genetic disorders, positions the other biologics segment as a key driver in the overall biologics market.

Segmentation 4: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

Asia-Pacific to Witness the Highest Growth in the Biologics Drug Discovery Market (by Region)

The biologics drug discovery market in the Asia-Pacific region is expected to witness a significant growth rate of 11.9% during the forecast period 2025-2035. This rapid expansion is driven by several key factors, including the increasing investment in biotechnology research, enhanced healthcare infrastructure, and a growing emphasis on personalized medicine. Asia-Pacific, with its diverse and rapidly evolving healthcare landscape, is witnessing significant advancements in biologics, particularly in countries including China, Japan, India, and South Korea, where governments and private organizations are heavily investing in biopharmaceutical research and development. The region's large and aging population, coupled with a rising burden of chronic diseases such as cancer, diabetes, and autoimmune disorders, has created a pressing need for innovative biologic therapies. Furthermore, the increasing adoption of cutting-edge technologies such as CRISPR and gene editing, alongside advancements in cell and gene therapies, is expected to fuel the region's dominance in biologics drug discovery. The Asia-Pacific market is also benefiting from the growing focus on biosimilars, which offer a cost-effective alternative to expensive biologic therapies, making them increasingly accessible to a wider patient base across the region.

Recent Developments in the Biologics Drug Discovery Market

  • In June 2025, AbbVie Inc. acquired Capstan Therapeutics, Inc. to advance in vivo CAR-T therapies for autoimmune diseases using Capstan's targeted lipid nanoparticle (tLNP) platform.
  • In January 2025, Evotec SE, in collaboration with Yonsei University and the Korean biotech company Zymedi, received a $4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF).
  • In January 2024, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. launched RenBiologics, a sub-brand dedicated to out-licensing its fully human antibody library and RenMice discovery platforms, enabling global partnerships and co-development for antibody-based therapeutics.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Rising Prevalence of Chronic and Rare Diseases Driving Biologics Demand: The growing need for innovative treatments in chronic and rare diseases is fueling the demand for innovative biologics and their discovery. Chronic conditions such as cancer, autoimmune disorders, and cardiovascular diseases continue to challenge healthcare systems worldwide. Biologics, with their ability to target specific molecular pathways, offer effective solutions for these complex diseases. Additionally, the increasing prevalence of rare diseases, which often lack viable treatments, further emphasizes the importance of biologics in addressing unmet medical needs. Therapies such as monoclonal antibodies, recombinant proteins, gene therapies, and enzyme replacement therapies are leading the way in treating these conditions. As the global healthcare landscape evolves and the need for advanced, targeted therapies rises, novel biologics drug discovery is anticipated to play a prominent role in shaping the future of medicine.

Market Challenges

High Development and Manufacturing Costs: The high costs associated with the drug discovery, development, and manufacturing of biologics present a significant challenge to market growth. Biologics, particularly those in the R&D phase or advanced stages of development, require substantial investment in research, production, and quality control. These processes are complex and resource-intensive, often involving cutting-edge technologies, specialized facilities, and stringent regulatory requirements. As a result, biologics tend to be more expensive than traditional small-molecule drugs, limiting their accessibility, particularly in resource-constrained or cost-sensitive healthcare environments. Additionally, the high price of biologic therapies, coupled with the need for ongoing research and development, places a strain on healthcare systems and patient affordability. These financial barriers limit access to biologics in underserved regions and among economically disadvantaged populations. Overcoming these challenges will be essential for advancing biologics drug discovery, expanding the reach of biologic treatments, and ensuring their broader adoption across diverse healthcare settings.

Market Opportunities

AI Integration in Biologics Drug Discovery: The integration of artificial intelligence (AI) into biologics drug discovery presents a significant growth opportunity, driven by the potential for faster, more efficient, and cost-effective development of biologic therapies. AI technologies, including machine learning and deep learning, are enabling more accurate prediction of molecular interactions, optimizing drug design, and streamlining the discovery of novel biologic candidates. As AI continues to evolve, its ability to analyze vast datasets, such as genetic information, clinical trial data, and protein structures, has the potential to accelerate the identification of high-potential drug targets and improve the precision of biologics development. In regions including North America and Europe, where there is a strong focus on innovation and advanced healthcare technologies, AI integration in biologics drug discovery is gaining traction. Additionally, collaborations between biopharma companies and AI technology providers are increasing, further enhancing the capabilities of biologics drug discovery platforms.

How can this report add value to an organization?

Product/Innovation Strategy: The global biologics drug discovery market has been extensively segmented based on various categories, such as method, manufacturing type, type, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and business expansions have accounted for the majority of key developments, comprising nearly 74% of the total developments in the global biologics drug discovery market between January 2022 and September 2025.

Competitive Strategy: The global biologics drug discovery market has numerous established players with product portfolios. Key players in the global biologics drug discovery market, analyzed and profiled in the study, include established players offering platforms, products, and services for biologics drug discovery.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2023 to 2035 have been considered for the global market size estimation, 2024 has been considered as the base year, and 2025 to 2035 as the forecast period.
  • The scope of this report has been carefully developed based on insights from experts across various companies worldwide. It presents a comprehensive market study of the platforms, products, and services within the biologics drug discovery market.
  • The market contribution of biologics drug discovery is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
  • Revenues from companies have been sourced from their annual reports for FY2023 and FY2024. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on the existing biologics drug discovery platforms, products, and services. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts in biologics drug discovery, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Alloy Therapeutics, Inc.
  • Charles River Laboratories International, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • WuXi Biologics (Cayman) Inc.
  • AbbVie Inc.
  • Amgen, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Novo Nordisk A/S
  • Novartis AG
  • Evotec SE
  • Eli Lilly and Company
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Johnson & Johnson
  • Pfizer, Inc.
  • F. Hoffmann-La Roche AG

Table of Contents

Executive Summary

Scope and Definition

1 Global Biologics Drug Discovery Market: Industry Outlook

  • 1.1 Market Overview
  • 1.2 Key Market Trends
    • 1.2.1 Growth of Bispecific and Multispecific Antibody Development
    • 1.2.2 Rising Partnerships and Collaborations
    • 1.2.3 Rising Demand for Outsourcing Services
  • 1.3 Regulatory Landscape
    • 1.3.1 U.S.
    • 1.3.2 Europe
      • 1.3.2.1 Germany
      • 1.3.2.2 France
      • 1.3.2.3 Italy
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 China
      • 1.3.3.2 Japan
    • 1.3.4 Rest-of-the-World
  • 1.4 Supply Chain Analysis
    • 1.4.1 Supply Chain and Risks within the Supply Chain
  • 1.5 Patent Analysis
    • 1.5.1 Patent Filing Trend (by Country)
    • 1.5.2 Patent Filing Trend (by Year)
  • 1.6 Market Dynamics
    • 1.6.1 Market Drivers
      • 1.6.1.1 Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics in Treatment
      • 1.6.1.2 Strong Investment and R&D Funding Leading to Increased Demand for Biologics
    • 1.6.2 Market Challenges
      • 1.6.2.1 High Development and Manufacturing Costs Hindering the Growth of the Market
    • 1.6.3 Market Opportunities
      • 1.6.3.1 AI Integration in Biologics Discovery

2 Global Biologics Drug Discovery Market (by Method), ($Billion), 2023-2035

  • 2.1 Target Identification/Validation
    • 2.1.1 Functional Genomics/Proteomics
    • 2.1.2 Cell-Based Assay
    • 2.1.3 CRISPR/Knockout Studies/Cas9
    • 2.1.4 Animal/Disease-Based Models
    • 2.1.5 Computational/In-Silico/Bioinformatics
  • 2.2 Hit Generation/Validation
    • 2.2.1 mAb Sequencing
    • 2.2.2 Hybridoma Screening
    • 2.2.3 Customized Synthetic Library Screening
    • 2.2.4 Phage Display Screening
    • 2.2.5 High-Throughput Screening
    • 2.2.6 Others
  • 2.3 Lead Identification
    • 2.3.1 Phage Display
    • 2.3.2 ELISA/ADCC and CDC Assay
    • 2.3.3 Array-Based Screening
    • 2.3.4 Hybridoma Screening and Humanization
    • 2.3.5 Bioanalytical Analysis
    • 2.3.6 Other Assays
  • 2.4 Lead Optimization
    • 2.4.1 Humanization
    • 2.4.2 Affinity Analysis
    • 2.4.3 Protein Engineering
    • 2.4.4 In-Vitro/In-Vivo Efficacy Assays
    • 2.4.5 Others

3 Global Biologics Drug Discovery Market (by Manufacturing Type), ($Billion), 2023-2035

  • 3.1 In-House Manufacturing
  • 3.2 Outsourced Manufacturing

4 Global Biologics Drug Discovery Market (by Type), ($Billion), 2023-2035

  • 4.1 Monoclonal Antibodies
    • 4.1.1 Monoclonal Antibodies Drug Discovery Market, by Method
      • 4.1.1.1 Monoclonal Antibodies Drug Discovery Market, by Method, Target Identification/Validation
      • 4.1.1.2 Monoclonal Antibodies Drug Discovery Market, by Method, Hit Generation/Validation
      • 4.1.1.3 Monoclonal Antibodies Drug Discovery Market, by Method, Lead Identification
      • 4.1.1.4 Monoclonal Antibodies Drug Discovery Market, by Method, Lead Optimization
  • 4.2 Recombinant Proteins
    • 4.2.1 Recombinant Proteins Drug Discovery Market, by Method
      • 4.2.1.1 Recombinant Proteins Drug Discovery Market, by Method, Target Identification/Validation
      • 4.2.1.2 Recombinant Proteins Drug Discovery Market, by Method, Hit Generation/Validation
      • 4.2.1.3 Recombinant Proteins Drug Discovery Market, by Method, Lead Identification
      • 4.2.1.4 Recombinant Proteins Drug Discovery Market, by Method, Lead Optimization
  • 4.3 Other Biologics

5 Global Biologics Drug Discovery Market (by Region), ($Billion), 2023-2035

  • 5.1 North America
    • 5.1.1 Regional Overview
    • 5.1.2 Driving Factors for Market Growth
    • 5.1.3 Factors Challenging the Market
    • 5.1.4 Market Sizing and Forecast
      • 5.1.4.1 North America Biologics Drug Discovery Market, by Manufacturing Type
      • 5.1.4.2 North America Biologics Drug Discovery Market, by Type
      • 5.1.4.3 North America Biologics Drug Discovery Market, by Country
        • 5.1.4.3.1 U.S.
          • 5.1.4.3.1.1 Country Overview
          • 5.1.4.3.1.2 Driving Factors for Market Growth
          • 5.1.4.3.1.3 Factors Challenging the Market
          • 5.1.4.3.1.4 Market Sizing and Forecast
          • 5.1.4.3.1.4.1 U.S. Biologics Drug Discovery Market, by Manufacturing Type
          • 5.1.4.3.1.4.2 U.S. Biologics Drug Discovery Market, by Type
        • 5.1.4.3.2 Canada
          • 5.1.4.3.2.1 Country Overview
          • 5.1.4.3.2.2 Driving Factors for Market Growth
          • 5.1.4.3.2.3 Factors Challenging the Market
          • 5.1.4.3.2.4 Market Sizing and Forecast
          • 5.1.4.3.2.4.1 Canada Biologics Drug Discovery Market, by Manufacturing Type
          • 5.1.4.3.2.4.2 Canada Biologics Drug Discovery Market, by Type
  • 5.2 Europe
    • 5.2.1 Regional Overview
    • 5.2.2 Driving Factors for Market Growth
    • 5.2.3 Factors Challenging the Market
    • 5.2.4 Market Sizing and Forecast
      • 5.2.4.1 Europe Biologics Drug Discovery Market, by Manufacturing Type
      • 5.2.4.2 Europe Biologics Drug Discovery Market, by Type
      • 5.2.4.3 Europe Biologics Drug Discovery Market, by Country
        • 5.2.4.3.1 Germany
          • 5.2.4.3.1.1 Country Overview
          • 5.2.4.3.1.2 Driving Factors for Market Growth
          • 5.2.4.3.1.3 Factors Challenging the Market
          • 5.2.4.3.1.4 Market Sizing and Forecast
          • 5.2.4.3.1.4.1 Germany Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.1.4.2 Germany Biologics Drug Discovery Market, by Type
        • 5.2.4.3.2 U.K.
          • 5.2.4.3.2.1 Country Overview
          • 5.2.4.3.2.2 Driving Factors for Market Growth
          • 5.2.4.3.2.3 Factors Challenging the Market
          • 5.2.4.3.2.4 Market Sizing and Forecast
          • 5.2.4.3.2.4.1 U.K. Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.2.4.2 U.K. Biologics Drug Discovery Market, by Type
        • 5.2.4.3.3 France
          • 5.2.4.3.3.1 Country Overview
          • 5.2.4.3.3.2 Driving Factors for Market Growth
          • 5.2.4.3.3.3 Factors Challenging the Market
          • 5.2.4.3.3.4 Market Sizing and Forecast
          • 5.2.4.3.3.4.1 France Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.3.4.2 France Biologics Drug Discovery Market, by Type
        • 5.2.4.3.4 Italy
          • 5.2.4.3.4.1 Country Overview
          • 5.2.4.3.4.2 Driving Factors for Market Growth
          • 5.2.4.3.4.3 Factors Challenging the Market
          • 5.2.4.3.4.4 Market Sizing and Forecast
          • 5.2.4.3.4.4.1 Italy Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.4.4.2 Italy Biologics Drug Discovery Market, by Type
        • 5.2.4.3.5 Spain
          • 5.2.4.3.5.1 Country Overview
          • 5.2.4.3.5.2 Driving Factors for Market Growth
          • 5.2.4.3.5.3 Factors Challenging the Market
          • 5.2.4.3.5.4 Market Sizing and Forecast
          • 5.2.4.3.5.4.1 Spain Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.5.4.2 Spain Biologics Drug Discovery Market, by Type
        • 5.2.4.3.6 Rest-of-Europe
          • 5.2.4.3.6.1 Country Overview
          • 5.2.4.3.6.2 Driving Factors for Market Growth
          • 5.2.4.3.6.3 Factors Challenging the Market
          • 5.2.4.3.6.4 Market Sizing and Forecast
          • 5.2.4.3.6.4.1 Rest-of-Europe Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.6.4.2 Rest-of-Europe Biologics Drug Discovery Market, by Type
  • 5.3 Asia-Pacific
    • 5.3.1 Regional Overview
    • 5.3.2 Driving Factors for Market Growth
    • 5.3.3 Factors Challenging the Market
    • 5.3.4 Market Sizing and Forecast
      • 5.3.4.1 Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
      • 5.3.4.2 Asia-Pacific Biologics Drug Discovery Market, by Type
      • 5.3.4.3 Asia-Pacific Biologics Drug Discovery Market, by Country
        • 5.3.4.3.1 China
          • 5.3.4.3.1.1 Country Overview
          • 5.3.4.3.1.2 Driving Factors for Market Growth
          • 5.3.4.3.1.3 Factors Challenging the Market
          • 5.3.4.3.1.4 Market Sizing and Forecast
          • 5.3.4.3.1.4.1 China Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.1.4.2 China Biologics Drug Discovery Market, by Type
        • 5.3.4.3.2 Japan
          • 5.3.4.3.2.1 Country Overview
          • 5.3.4.3.2.2 Driving Factors for Market Growth
          • 5.3.4.3.2.3 Factors Challenging the Market
          • 5.3.4.3.2.4 Market Sizing and Forecast
          • 5.3.4.3.2.4.1 Japan Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.2.4.2 Japan Biologics Drug Discovery Market, by Type
        • 5.3.4.3.3 India
          • 5.3.4.3.3.1 Country Overview
          • 5.3.4.3.3.2 Driving Factors for Market Growth
          • 5.3.4.3.3.3 Factors Challenging the Market
          • 5.3.4.3.3.4 Market Sizing and Forecast
          • 5.3.4.3.3.4.1 India Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.3.4.2 India Biologics Drug Discovery Market, by Type
        • 5.3.4.3.4 South Korea
          • 5.3.4.3.4.1 Country Overview
          • 5.3.4.3.4.2 Driving Factors for Market Growth
          • 5.3.4.3.4.3 Factors Challenging the Market
          • 5.3.4.3.4.4 Market Sizing and Forecast
          • 5.3.4.3.4.4.1 South Korea Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.4.4.2 South Korea Biologics Drug Discovery Market, by Type
        • 5.3.4.3.5 Australia
          • 5.3.4.3.5.1 Country Overview
          • 5.3.4.3.5.2 Driving Factors for Market Growth
          • 5.3.4.3.5.3 Factors Challenging the Market
          • 5.3.4.3.5.4 Market Sizing and Forecast
          • 5.3.4.3.5.4.1 Australia Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.5.4.2 Australia Biologics Drug Discovery Market, by Type
        • 5.3.4.3.6 Rest-of-Asia-Pacific
          • 5.3.4.3.6.1 Country Overview
          • 5.3.4.3.6.2 Driving Factors for Market Growth
          • 5.3.4.3.6.3 Factors Challenging the Market
          • 5.3.4.3.6.4 Market Sizing and Forecast
          • 5.3.4.3.6.4.1 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.6.4.2 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Type
  • 5.4 Rest-of-the-World
    • 5.4.1 Regional Overview
    • 5.4.2 Driving Factors for Market Growth
    • 5.4.3 Factors Challenging the Market
    • 5.4.4 Market Sizing and Forecast
      • 5.4.4.1 Rest-of-the-World Biologics Drug Discovery Market, by Manufacturing Type
      • 5.4.4.2 Rest-of-the-World Biologics Drug Discovery Market, by Type

6 Competitive Benchmarking and Company Profiles

  • 6.1 Key Strategies and Developments by Company
    • 6.1.1 Funding Activities
    • 6.1.2 Mergers and Acquisitions
    • 6.1.3 Regulatory Approvals and Product Launches
    • 6.1.4 Partnerships, Collaborations, and Business Expansions
  • 6.2 Company Profiles
    • 6.2.1 Alloy Therapeutics, Inc.
      • 6.2.1.1 Overview
      • 6.2.1.2 Top Products/Product Portfolio
      • 6.2.1.3 Top Competitors
      • 6.2.1.4 Target Customers
      • 6.2.1.5 Key Personal
      • 6.2.1.6 Analyst View
    • 6.2.2 AbbVie Inc.
      • 6.2.2.1 Overview
      • 6.2.2.2 Top Products/Product Portfolio
      • 6.2.2.3 Top Competitors
      • 6.2.2.4 Target Customers
      • 6.2.2.5 Key Personal
      • 6.2.2.6 Analyst View
    • 6.2.3 Amgen, Inc.
      • 6.2.3.1 Overview
      • 6.2.3.2 Top Products/Product Portfolio
      • 6.2.3.3 Top Competitors
      • 6.2.3.4 Target Customers
      • 6.2.3.5 Key Personal
      • 6.2.3.6 Analyst View
    • 6.2.4 Astellas Pharma Inc.
      • 6.2.4.1 Overview
      • 6.2.4.2 Top Products/Product Portfolio
      • 6.2.4.3 Top Competitors
      • 6.2.4.4 Target Customers
      • 6.2.4.5 Key Personal
      • 6.2.4.6 Analyst View
    • 6.2.5 AstraZeneca Plc
      • 6.2.5.1 Overview
      • 6.2.5.2 Top Products/Product Portfolio
      • 6.2.5.3 Top Competitors
      • 6.2.5.4 Target Customers
      • 6.2.5.5 Key Personal
      • 6.2.5.6 Analyst View
    • 6.2.6 Charles River Laboratories International, Inc.
      • 6.2.6.1 Overview
      • 6.2.6.2 Top Products/Product Portfolio
      • 6.2.6.3 Top Competitors
      • 6.2.6.4 Target Customers
      • 6.2.6.5 Key Personal
      • 6.2.6.6 Analyst View
    • 6.2.7 Eli Lilly and Company
      • 6.2.7.1 Overview
      • 6.2.7.2 Top Products/Product Portfolio
      • 6.2.7.3 Top Competitors
      • 6.2.7.4 Target Customers
      • 6.2.7.5 Key Personal
      • 6.2.7.6 Analyst View
    • 6.2.8 Evotec SE
      • 6.2.8.1 Overview
      • 6.2.8.2 Top Products/Product Portfolio
      • 6.2.8.3 Top Competitors
      • 6.2.8.4 Target Customers
      • 6.2.8.5 Key Personal
      • 6.2.8.6 Analyst View
    • 6.2.9 F. Hoffmann-La Roche AG
      • 6.2.9.1 Overview
      • 6.2.9.2 Top Products/Product Portfolio
      • 6.2.9.3 Top Competitors
      • 6.2.9.4 Target Customers
      • 6.2.9.5 Key Personal
      • 6.2.9.6 Analyst View
    • 6.2.10 GenScript Biotech Corporation
      • 6.2.10.1 Overview
      • 6.2.10.2 Top Products/Product Portfolio
      • 6.2.10.3 Top Competitors
      • 6.2.10.4 Target Customers
      • 6.2.10.5 Key Personal
      • 6.2.10.6 Analyst View
    • 6.2.11 Gilead Sciences, Inc.
      • 6.2.11.1 Overview
      • 6.2.11.2 Top Products/Product Portfolio
      • 6.2.11.3 Top Competitors
      • 6.2.11.4 Target Customers
      • 6.2.11.5 Key Personal
      • 6.2.11.6 Analyst View
    • 6.2.12 Johnson & Johnson
      • 6.2.12.1 Overview
      • 6.2.12.2 Top Products/Product Portfolio
      • 6.2.12.3 Top Competitors
      • 6.2.12.4 Target Customers
      • 6.2.12.5 Key Personal
      • 6.2.12.6 Analyst View
    • 6.2.13 Merck KGaA
      • 6.2.13.1 Overview
      • 6.2.13.2 Top Products/Product Portfolio
      • 6.2.13.3 Top Competitors
      • 6.2.13.4 Target Customers
      • 6.2.13.5 Key Personal
      • 6.2.13.6 Analyst View
    • 6.2.14 Novo Nordisk A/S
      • 6.2.14.1 Overview
      • 6.2.14.2 Top Products/Product Portfolio
      • 6.2.14.3 Top Competitors
      • 6.2.14.4 Target Customers
      • 6.2.14.5 Key Personal
      • 6.2.14.6 Analyst View
    • 6.2.15 Novartis AG
      • 6.2.15.1 Overview
      • 6.2.15.2 Top Products/Product Portfolio
      • 6.2.15.3 Top Competitors
      • 6.2.15.4 Target Customers
      • 6.2.15.5 Key Personal
      • 6.2.15.6 Analyst View
    • 6.2.16 Pfizer, Inc.
      • 6.2.16.1 Overview
      • 6.2.16.2 Top Products/Product Portfolio
      • 6.2.16.3 Top Competitors
      • 6.2.16.4 Target Customers
      • 6.2.16.5 Key Personal
      • 6.2.16.6 Analyst View
    • 6.2.17 Regeneron Pharmaceuticals, Inc.
      • 6.2.17.1 Overview
      • 6.2.17.2 Top Products/Product Portfolio
      • 6.2.17.3 Top Competitors
      • 6.2.17.4 Target Customers
      • 6.2.17.5 Key Personal
      • 6.2.17.6 Analyst View
    • 6.2.18 WuXi Biologics (Cayman) Inc.
      • 6.2.18.1 Overview
      • 6.2.18.2 Top Products/Product Portfolio
      • 6.2.18.3 Top Competitors
      • 6.2.18.4 Target Customers
      • 6.2.18.5 Key Personal
      • 6.2.18.6 Analyst View

7 Research Methodology

  • 7.1 Data Sources
    • 7.1.1 Primary Data Sources
    • 7.1.2 Secondary Data Sources
    • 7.1.3 Data Triangulation
  • 7.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Biologics Drug Discovery Market (by Scenario), $Billion, 2024, 2029, and 2035
  • Figure 2: Global Biologics Drug Discovery Market, 2024 and 2035
  • Figure 3: Top Countries, Global Biologics Drugs Discovery Market, $Billion, 2024
  • Figure 4: Global Biologics Drug Discovery Market, $Billion, 2025 and 2035
  • Figure 5: Global Biologics Drug Discovery Market (by Method), $Billion, 2025, 2029, and 2035
  • Figure 6: Global Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
  • Figure 7: Global Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
  • Figure 8: Number of Patents Filed (by Country), January 2021 to 12th September 2025
  • Figure 9: Number of Patents Filed (by Year), January 2021 to 12th September 2025
  • Figure 10: Incidence of Cancer (by Region), 2020-2040
  • Figure 11: Global Biologics Drug Discovery Market (by Method), $Billion, 2025, 2029, and 2035
  • Figure 12: Global Biologics Drug Discovery Market (Target Identification/Validation), $Billion, 2023-2035
  • Figure 13: Global Biologics Drug Discovery Market (Functional Genomics/Proteomics), $Billion, 2023-2035
  • Figure 14: Global Biologics Drug Discovery Market (Cell-Based Assay), $Billion, 2023-2035
  • Figure 15: Global Biologics Drug Discovery Market (CRISPR/Knockout Studies/Cas9), $Billion, 2023-2035
  • Figure 16: Global Biologics Drug Discovery Market (Animal/Disease-Based Models), $Billion, 2023-2035
  • Figure 17: Global Biologics Drug Discovery Market (Computational/In-Silico/Bioinformatics), $Billion, 2023-2035
  • Figure 18: Global Biologics Drug Discovery Market (Hit Generation/Validation), $Billion, 2023-2035
  • Figure 19: Global Biologics Drug Discovery Market (mAb Sequencing), $Billion, 2023-2035
  • Figure 20: Global Biologics Drug Discovery Market (Hybridoma Screening), $Billion, 2023-2035
  • Figure 21: Global Biologics Drug Discovery Market (Customized Synthetic Library Screening), $Billion, 2023-2035
  • Figure 22: Global Biologics Drug Discovery Market (Phage Display Screening), $Billion, 2023-2035
  • Figure 23: Global Biologics Drug Discovery Market (High-Throughput Screening), $Billion, 2023-2035
  • Figure 24: Global Biologics Drug Discovery Market (Others), $Billion, 2023-2035
  • Figure 25: Global Biologics Drug Discovery Market (Lead Identification), $Billion, 2023-2035
  • Figure 26: Global Biologics Drug Discovery Market (Phage Display), $Billion, 2023-2035
  • Figure 27: Global Biologics Drug Discovery Market (ELISA/ADCC and CDC Assay), $Billion, 2023-2035
  • Figure 28: Global Biologics Drug Discovery Market (Array-Based Screening), $Billion, 2023-2035
  • Figure 29: Global Biologics Drug Discovery Market (Hybridoma Screening and Humanization), $Billion, 2023-2035
  • Figure 30: Global Biologics Drug Discovery Market (Bioanalytical Analysis), $Billion, 2023-2035
  • Figure 31: Global Biologics Drug Discovery Market (Other Assays), $Billion, 2023-2035
  • Figure 32: Global Biologics Drug Discovery Market (Lead Optimization), $Billion, 2023-2035
  • Figure 33: Global Biologics Drug Discovery Market (Humanization), $Billion, 2023-2035
  • Figure 34: Global Biologics Drug Discovery Market (Affinity Analysis), $Billion, 2023-2035
  • Figure 35: Global Biologics Drug Discovery Market (Protein Engineering), $Billion, 2023-2035
  • Figure 36: Global Biologics Drug Discovery Market (In-Vitro/In-Vivo Efficacy Assays), $Billion, 2023-2035
  • Figure 37: Global Biologics Drug Discovery Market (Others), $Billion, 2023-2035
  • Figure 38: Global Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
  • Figure 39: Global Biologics Drug Discovery Market (In-House Manufacturing), $Billion, 2023-2035
  • Figure 40: Advantages of Outsourcing Drug Development Operations
  • Figure 41: Global Biologics Drug Discovery Market (Outsourced Manufacturing), $Billion, 2023-2035
  • Figure 42: Global Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
  • Figure 43: Global Biologics Drug Discovery Market (Monoclonal Antibodies), $Billion, 2023-2035
  • Figure 44: Global Biologics Drug Discovery Market (Recombinant Proteins), $Billion, 2023-2035
  • Figure 45: Global Biologics Drug Discovery Market (Other Biologics), $Billion, 2023-2035
  • Figure 46: North America Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 47: U.S. Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 48: Canada Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 49: Europe Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 50: Germany Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 51: U.K. Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 52: France Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 53: Italy Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 54: Spain Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 55: Rest-of-Europe Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 56: Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 57: China Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 58: Japan Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 59: India Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 60: South Korea Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 61: Australia Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 62: Rest-of-Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 63: Rest-of-the-World Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 64: Data Triangulation
  • Figure 65: Top-Down and Bottom-Up Approach
  • Figure 66: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Biologics Drug Discovery Market, Key Market Trends
  • Table 3: Key Partnerships in the Biologics Drug Discovery Market
  • Table 4: Market Dynamics
  • Table 5: Monoclonal Antibodies Drug Discovery Market (by Method), $Billion, 2023-2035
  • Table 6: Monoclonal Antibodies Drug Discovery Market, (by Method, Target Identification/Validation), $Billion, 2023-2035
  • Table 7: Monoclonal Antibodies Drug Discovery Market, (by Method, Hit Generation/Validation), $Billion, 2023-2035
  • Table 8: Monoclonal Antibodies Drug Discovery Market, (by Method, Lead Identification), $Billion, 2023-2035
  • Table 9: Monoclonal Antibodies Drug Discovery Market, (by Method, Lead Optimization), $Billion, 2023-2035
  • Table 10: Recombinant Proteins Drug Discovery Market (by Method), $Billion, 2023-2035
  • Table 11: Recombinant Proteins Drug Discovery Market, (by Method, Target Identification/Validation), $Billion, 2023-2035
  • Table 12: Recombinant Proteins Drug Discovery Market, (by Method, Hit Generation/Validation), $Billion, 2023-2035
  • Table 13: Recombinant Proteins Drug Discovery Market, (by Method, Lead Identification), $Billion, 2023-2035
  • Table 14: Recombinant Proteins Drug Discovery Market, (by Method, Lead Optimization), $Billion, 2023-2035
  • Table 15: Global Biologics Drug Discovery Market (by Region), $Billion, 2023-2035
  • Table 16: North America Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 17: North America Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 18: North America Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
  • Table 19: U.S. Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 20: U.S. Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 21: Canada Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 22: Canada Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 23: Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 24: Europe Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 25: Europe Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
  • Table 26: Germany Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 27: Germany Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 28: U.K. Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 29: U.K. Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 30: France Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 31: France Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 32: Italy Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 33: Italy Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 34: Spain Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 35: Spain Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 36: Rest-of-Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 37: Rest-of-Europe Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 38: Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 39: Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 40: Asia-Pacific Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
  • Table 41: China Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 42: China Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 43: Japan Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 44: Japan Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 45: India Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 46: India Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 47: South Korea Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 48: South Korea Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 49: Australia Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 50: Australia Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 51: Rest-of-Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 52: Rest-of-Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 53: Rest-of-the-World Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 54: Rest-of-the-World Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 55: Some of the Major Key Strategies: Funding Activities, January 2022 - September 2025
  • Table 56: Some of the Major Key Strategies: Mergers and Acquisitions, January 2022 - September 2025
  • Table 57: Some of the Major Key Strategies: Regulatory Approvals and Product Launches, January 2022 - September 2025
  • Table 58: Some of the Major Key Strategies: Partnerships, Collaborations, and Business Expansions, January 2022 - September 2025